| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Emergence of drug resistant virus in treatment of viral infections is an unavoidable problem and the evaluation of drug resistant is an important theme among that. We developed a new evaluation method for drug resistant virus with a docking study, using known crystal structure and the mutation information. We applied this method to atazanavir and oseltamivir for the purpose of extending the scope of this method. Evaluating resistance to atazanavir for 30 kinds HIV-1 protease, including wild type and 29 variants, it was possible to assess the strong atazanavir-resistant protease. Further, we also applied this method to the H1N1 subtype and B type neuraminidase, to each type including wild type, resistant variant and strong resistant variant, it was possible to evaluate the strong resistant variants of H1N1 subtype and B type neuraminidase.
|
